A 42-year-old woman from Delhi presents with a 6-month history of symmetrical pain and swelling of the small joints of both hands, wrists, and knees. Morning stiffness lasts 2 hours. On examination, she has soft tissue swelling over the PIP and MCP joints bilaterally, with mild ulnar deviation of the fingers. Laboratory investigations show: ESR 68 mm/hr, CRP 12 mg/dL, RF 120 IU/mL (normal <20), anti-CCP antibody 85 U/mL (normal <20). X-ray of hands shows periarticular osteopenia and early marginal erosions. She has no extra-articular manifestations. What is the most appropriate next step in management?

Explanation

## Diagnosis and Classification **Key Point:** This patient has established seropositive RA (RF+, anti-CCP+) with erosive disease and functional impairment — meeting ACR/EULAR 2010 classification criteria. The presence of erosions on imaging indicates structural damage and poor prognosis. ## Treatment Strategy **High-Yield:** Current ACR/EULAR guidelines recommend **early initiation of conventional DMARDs (cDMARDs) within 3 months of symptom onset** in all patients with RA, regardless of disease activity or serology. Methotrexate is the anchor drug and first-line DMARD. **Clinical Pearl:** Early DMARD therapy ("treat-to-target" strategy) is the standard of care and has been shown to slow or halt radiological progression, reduce disability, and improve long-term outcomes. Delaying DMARDs allows irreversible joint damage to accumulate. ### Why Methotrexate? | Feature | Methotrexate | |---------|---------------| | **Efficacy** | Gold standard; 60–70% achieve low disease activity | | **Onset** | 6–12 weeks | | **Monitoring** | CBC, LFTs every 8–12 weeks | | **Folic acid** | 5 mg daily (or 5 mg × 2 on non-MTX days) to reduce toxicity | | **Pregnancy** | Teratogenic; counsel on contraception | **Mnemonic — DMARD Ladder:** **MISS** = Methotrexate (first), Immunosuppressants (azathioprine, mycophenolate), Sulfasalazine, Sulfhydryl compounds (gold, penicillamine). MTX is always the starting rung. ## Why Not the Other Options? - **NSAIDs + prednisolone alone:** Suppress symptoms but do NOT modify disease progression or prevent erosions. Low-dose prednisolone (≤7.5 mg/day) may be used adjunctively but is not monotherapy. - **Observation for 3 months:** Contraindicated in seropositive, erosive disease. Every month of delay increases cumulative joint damage. - **TNF inhibitor monotherapy:** Biologic agents are reserved for inadequate response to cDMARDs or when cDMARDs are contraindicated. Never used as monotherapy in treatment-naïve RA. [cite:Harrison 21e Ch 313]